Quantcast
Home > Quotes > MRNS
MRNS

Marinus Pharmaceuticals, Inc. Common Stock (MRNS) Quote & Summary Data

$4.2
*  
0.90
17.65%
Get MRNS Alerts
*Delayed - data as of Dec. 12, 2018  -  Find a broker to begin trading MRNS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MRNS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 4.67 / $ 4.10
Share Volume
4,001,239
50 Day Avg. Daily Volume
1,086,073
Previous Close
$ 5.10
52 Week High / Low
$ 10.54 / $ 3.31
Market Cap
170,205,055
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
4,001,239
50 Day Avg. Daily Volume:
1,086,073

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.86

Trading Range

The current last sale of $4.20 is 26.89% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.67 $ 10.54
 Low: $ 4.10 $ 3.31

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Our clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors.  ... More ...  


Risk Grade

Where does MRNS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.61
Open Date:
Dec. 12, 2018
Close Price:
$ 5.10
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info